This downregulation of S1PR1 and the consequent retention of lymphocytes within the lymph nodes has been exploited for the treatment of the relapsing and remitting form of multiple sclerosis, in order to alleviate autoimmunity symptoms [88]. This evidence concerns the gene S1PR1 and multiple sclerosis.